head and neck cancer

With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.

OncoDNA will provide patient-enrollment services for an ongoing clinical study of Kura's head and neck squamous cell carcinoma drug tipifarnib.

With integrated data for thousands of TCGA tumors, teams explored cancer subtypes, searched for prognostic insights, began mapping immune cell interactions, and more.

DCell, a visible neural network, uses deep learning techniques to model cellular behavior almost as accurately as has been observed in laboratory settings. 

Using RNA sequences for thousands of cells, researchers looked at head and neck squamous cell carcinomas and proposed streamlined expression subtypes.

The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.

The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.

Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.

New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.

Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.

Pages

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.